Sino Biopharmaceutical Ltd (HKG: 1177), a leading biotech company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its TQG3902 injection, which is under development to increase blood pressure in adults with septic shock or other distributed shock. This marks the first time a drug of its kind has entered the clinical phase in China.
Background on Giapreza and Its Approval in the US
The originator of TQG3902, Giapreza, is a vasoconstrictor developed by La Jolla Pharmaceutical Company, which was approved in the US in December 2017 for use in increasing blood pressure in adults with sepsis or other distributed shock. Giapreza is comprised of synthetic human angiotensin II, a peptide hormone that plays a crucial role in the renin–angiotensin–aldosterone system (RAAS).
Advantages of Angiotensin II in Vasoconstriction
Angiotensin II offers a wider dose range compared to standard vasopressin and does not lead to the generation of nitric oxide, which can be beneficial in managing blood pressure. As an endogenous hormone, it also provides an improved safety profile, making it a promising treatment option for patients with septic shock.-Fineline Info & Tech
